Skip to content
RecruitingN/A

Working Mechanisms and Effectiveness of IV Ketamine-assisted Psychotherapy on Depression in TRD Clients

NCT07706478 · Senz

Recruiting
Status
Accepting participants
Not applicable
Phase
120
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

Ketamine-Assisted Psychotherapy (KAP) is an innovative treatment that combines intravenous ketamine with psychotherapy in a carefully monitored clinical setting. At Senz, this treatment is being evaluated in an open-label clinical trial for individuals with persistent depression who have not responded sufficiently to previous treatments. The combination of ketamine, psychological support, and integration sessions aims to promote emotional processing, psychological flexibility, and lasting therapeutic change.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Beck Depression Inventory

    Measured over baseline/pre-intervention/post-intervention (end of treatment)/3months after post-intervention

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 70 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Adults (18 years and older) * TRD * A MADRS score above the established clinical cut-off, indicating clinically significant depressive symptoms * Insufficient response to at least two adequate antidepressant treatment trials and one evidence-based psychotherapy, or failure to achieve adequate improvement following at least three consecutive treatment steps in accordance with the Dutch Multidisciplinary Guideline for Depression Exclusion Criteria: * Current substance use disorder or recent illicit drug use * Substance use disorder not in remission for at least 3 months * Inability to abstain from alcohol for 24 hours before and after treatment * Acute suicidality * Current or past psychotic disorder * Significant neurological disorders (e.g., epilepsy, elevated intracranial pressure) * Uncontrolled hypertension or medical conditions associated with increased cardiovascular or cerebrovascular risk (e.g., aneurysms, recent myocardial infarction or intracerebral hemorrhage) * Significant bladder disease (e.g., cystitis) * Severe hepatic impairment * Pregnancy, breastfeeding, or ongoing IVF treatment * Extreme underweight or obesity where treatment is deemed medically unsafe Inability to arrange an accompanying adult for transport and support after treatment

Where

1 study site

FacilityCityRegionCountry
SENZDoornUtrechtNetherlands

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07706478 on ClinicalTrials.gov →

Last updated in the registry 2026-07-15. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits